| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Parkinson Disease | 312 | 2023 | 1164 | 29.120 |
Why?
|
| Movement Disorders | 47 | 2023 | 141 | 9.130 |
Why?
|
| Neurology | 45 | 2022 | 101 | 8.720 |
Why?
|
| Severity of Illness Index | 90 | 2023 | 1113 | 8.570 |
Why?
|
| Hallucinations | 40 | 2023 | 87 | 7.440 |
Why?
|
| Antiparkinson Agents | 59 | 2023 | 130 | 7.090 |
Why?
|
| Disability Evaluation | 29 | 2022 | 327 | 5.470 |
Why?
|
| Humans | 484 | 2023 | 29337 | 4.760 |
Why?
|
| Levodopa | 76 | 2023 | 142 | 4.200 |
Why?
|
| Dyskinesia, Drug-Induced | 30 | 2023 | 54 | 4.040 |
Why?
|
| Neurologic Examination | 29 | 2016 | 146 | 3.710 |
Why?
|
| Societies, Medical | 18 | 2022 | 190 | 3.300 |
Why?
|
| History, 19th Century | 52 | 2022 | 66 | 3.240 |
Why?
|
| Psychometrics | 21 | 2020 | 262 | 3.150 |
Why?
|
| Male | 242 | 2022 | 15621 | 2.820 |
Why?
|
| Dyskinesias | 12 | 2021 | 35 | 2.660 |
Why?
|
| Aged | 177 | 2022 | 9448 | 2.630 |
Why?
|
| Female | 221 | 2022 | 16197 | 2.600 |
Why?
|
| Middle Aged | 178 | 2022 | 9823 | 2.530 |
Why?
|
| Psychiatric Status Rating Scales | 18 | 2021 | 343 | 2.340 |
Why?
|
| Tourette Syndrome | 21 | 2009 | 37 | 2.220 |
Why?
|
| Tremor | 17 | 2023 | 141 | 2.130 |
Why?
|
| Neuropsychological Tests | 28 | 2022 | 1251 | 2.120 |
Why?
|
| Deep Brain Stimulation | 5 | 2022 | 74 | 2.000 |
Why?
|
| Dopamine Agents | 18 | 2016 | 40 | 1.910 |
Why?
|
| Placebo Effect | 9 | 2020 | 25 | 1.890 |
Why?
|
| Reproducibility of Results | 41 | 2021 | 788 | 1.870 |
Why?
|
| Surveys and Questionnaires | 23 | 2020 | 1184 | 1.790 |
Why?
|
| Sleep Wake Disorders | 10 | 2014 | 148 | 1.690 |
Why?
|
| Dystonia | 17 | 2013 | 53 | 1.680 |
Why?
|
| Antipsychotic Agents | 23 | 2011 | 82 | 1.650 |
Why?
|
| Psychotic Disorders | 8 | 2011 | 43 | 1.620 |
Why?
|
| Activities of Daily Living | 22 | 2019 | 501 | 1.600 |
Why?
|
| History, 20th Century | 27 | 2017 | 84 | 1.560 |
Why?
|
| Supranuclear Palsy, Progressive | 13 | 2020 | 44 | 1.540 |
Why?
|
| Cognition Disorders | 20 | 2018 | 1011 | 1.490 |
Why?
|
| Disease Progression | 29 | 2021 | 787 | 1.460 |
Why?
|
| Videotape Recording | 17 | 2011 | 43 | 1.440 |
Why?
|
| Dopamine Agonists | 10 | 2011 | 46 | 1.330 |
Why?
|
| Movement | 12 | 2018 | 143 | 1.300 |
Why?
|
| Mental Status and Dementia Tests | 12 | 2023 | 80 | 1.290 |
Why?
|
| Dementia | 15 | 2014 | 521 | 1.290 |
Why?
|
| Quality of Life | 11 | 2020 | 662 | 1.210 |
Why?
|
| France | 20 | 2022 | 37 | 1.190 |
Why?
|
| Aged, 80 and over | 45 | 2021 | 4851 | 1.190 |
Why?
|
| Torticollis | 8 | 2021 | 69 | 1.160 |
Why?
|
| Telemedicine | 4 | 2022 | 99 | 1.140 |
Why?
|
| Heterozygote | 4 | 2022 | 103 | 1.130 |
Why?
|
| Adult | 91 | 2020 | 8601 | 1.130 |
Why?
|
| Evaluation Studies as Topic | 6 | 2010 | 56 | 1.090 |
Why?
|
| Tic Disorders | 8 | 2017 | 17 | 1.080 |
Why?
|
| Carbidopa | 26 | 2009 | 45 | 1.060 |
Why?
|
| Glucosylceramidase | 2 | 2022 | 26 | 1.060 |
Why?
|
| Nervous System Diseases | 9 | 2020 | 145 | 1.060 |
Why?
|
| Fetal Tissue Transplantation | 13 | 2008 | 35 | 1.050 |
Why?
|
| Subthalamic Nucleus | 3 | 2022 | 32 | 1.050 |
Why?
|
| Cerebral Cortex | 9 | 2020 | 195 | 1.050 |
Why?
|
| Double-Blind Method | 32 | 2021 | 503 | 1.010 |
Why?
|
| Gait Disorders, Neurologic | 6 | 2017 | 144 | 0.970 |
Why?
|
| Disruptive, Impulse Control, and Conduct Disorders | 2 | 2020 | 10 | 0.950 |
Why?
|
| Amantadine | 10 | 2017 | 15 | 0.950 |
Why?
|
| Huntington Disease | 8 | 2018 | 60 | 0.930 |
Why?
|
| Emotions | 3 | 2015 | 90 | 0.890 |
Why?
|
| Adrenal Medulla | 16 | 1997 | 31 | 0.880 |
Why?
|
| Motor Skills | 5 | 2020 | 61 | 0.870 |
Why?
|
| Teaching | 5 | 2009 | 62 | 0.850 |
Why?
|
| Neuroprotective Agents | 4 | 2014 | 59 | 0.840 |
Why?
|
| Brain | 20 | 2023 | 1689 | 0.840 |
Why?
|
| Mentoring | 1 | 2022 | 29 | 0.810 |
Why?
|
| Placebos | 7 | 2012 | 77 | 0.810 |
Why?
|
| Dopamine | 19 | 2011 | 156 | 0.800 |
Why?
|
| Depressive Disorder | 3 | 2013 | 187 | 0.790 |
Why?
|
| Apathy | 1 | 2020 | 2 | 0.780 |
Why?
|
| Postural Balance | 4 | 2018 | 121 | 0.770 |
Why?
|
| Vibration | 2 | 2012 | 26 | 0.770 |
Why?
|
| Corpus Striatum | 15 | 2005 | 111 | 0.750 |
Why?
|
| Medical Illustration | 4 | 2010 | 20 | 0.730 |
Why?
|
| Thiazoles | 6 | 2005 | 35 | 0.730 |
Why?
|
| Longitudinal Studies | 19 | 2021 | 1442 | 0.730 |
Why?
|
| Cross-Sectional Studies | 10 | 2022 | 959 | 0.720 |
Why?
|
| Psychomotor Performance | 9 | 2013 | 216 | 0.720 |
Why?
|
| Forensic Psychiatry | 2 | 2013 | 4 | 0.720 |
Why?
|
| Fatigue | 3 | 2016 | 59 | 0.720 |
Why?
|
| Clinical Trials as Topic | 17 | 2012 | 324 | 0.710 |
Why?
|
| Indans | 4 | 2006 | 9 | 0.690 |
Why?
|
| Nocebo Effect | 1 | 2018 | 2 | 0.670 |
Why?
|
| Cognition | 6 | 2022 | 1277 | 0.670 |
Why?
|
| Biomedical Research | 3 | 2016 | 81 | 0.670 |
Why?
|
| Polymorphism, Single Nucleotide | 7 | 2018 | 306 | 0.660 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 3 | 2014 | 42 | 0.660 |
Why?
|
| Substantia Nigra | 10 | 2016 | 148 | 0.660 |
Why?
|
| Follow-Up Studies | 22 | 2019 | 1830 | 0.660 |
Why?
|
| Uric Acid | 5 | 2022 | 13 | 0.650 |
Why?
|
| Factor Analysis, Statistical | 10 | 2023 | 77 | 0.640 |
Why?
|
| Monoamine Oxidase Inhibitors | 3 | 2006 | 20 | 0.630 |
Why?
|
| Anticonvulsants | 2 | 2017 | 109 | 0.620 |
Why?
|
| Societies, Scientific | 4 | 2015 | 12 | 0.610 |
Why?
|
| Fragile X Syndrome | 5 | 2009 | 189 | 0.590 |
Why?
|
| Hypotension, Orthostatic | 3 | 2011 | 16 | 0.580 |
Why?
|
| Visual Pathways | 3 | 2014 | 8 | 0.580 |
Why?
|
| Hysteria | 2 | 2016 | 2 | 0.580 |
Why?
|
| Magnetic Resonance Imaging | 8 | 2014 | 1221 | 0.580 |
Why?
|
| United States | 21 | 2014 | 2333 | 0.570 |
Why?
|
| Chorea | 8 | 2001 | 13 | 0.570 |
Why?
|
| International Cooperation | 7 | 2018 | 32 | 0.570 |
Why?
|
| Hospitals, University | 2 | 2014 | 39 | 0.570 |
Why?
|
| Physicians | 3 | 2017 | 115 | 0.570 |
Why?
|
| Compulsive Behavior | 2 | 2019 | 6 | 0.550 |
Why?
|
| Dose-Response Relationship, Drug | 18 | 2017 | 437 | 0.540 |
Why?
|
| Gastrointestinal Microbiome | 3 | 2023 | 180 | 0.540 |
Why?
|
| Depression | 4 | 2020 | 465 | 0.540 |
Why?
|
| Randomized Controlled Trials as Topic | 10 | 2011 | 340 | 0.540 |
Why?
|
| Sensitivity and Specificity | 10 | 2018 | 553 | 0.540 |
Why?
|
| Research Design | 4 | 2015 | 212 | 0.540 |
Why?
|
| Animals | 46 | 2022 | 4552 | 0.540 |
Why?
|
| Amygdala | 1 | 2015 | 50 | 0.540 |
Why?
|
| Mutation | 5 | 2022 | 383 | 0.530 |
Why?
|
| Photography | 3 | 2006 | 17 | 0.520 |
Why?
|
| Physical Therapy Modalities | 2 | 2012 | 80 | 0.520 |
Why?
|
| History, 21st Century | 5 | 2017 | 36 | 0.520 |
Why?
|
| Nerve Net | 2 | 2014 | 54 | 0.510 |
Why?
|
| Globus Pallidus | 5 | 2005 | 31 | 0.510 |
Why?
|
| Health Planning Guidelines | 4 | 2013 | 11 | 0.510 |
Why?
|
| Myoclonus | 9 | 2001 | 29 | 0.500 |
Why?
|
| Cohort Studies | 14 | 2018 | 1939 | 0.490 |
Why?
|
| Blindness | 1 | 2014 | 14 | 0.490 |
Why?
|
| Ataxia | 3 | 2005 | 79 | 0.490 |
Why?
|
| Multiple System Atrophy | 5 | 2022 | 42 | 0.480 |
Why?
|
| Behavioral Symptoms | 4 | 2017 | 13 | 0.470 |
Why?
|
| Time Factors | 25 | 2019 | 1616 | 0.470 |
Why?
|
| Parkinsonian Disorders | 4 | 2007 | 217 | 0.470 |
Why?
|
| Cholecystokinin | 2 | 2011 | 7 | 0.470 |
Why?
|
| Language | 5 | 2021 | 78 | 0.470 |
Why?
|
| Homicide | 1 | 2013 | 5 | 0.470 |
Why?
|
| Suicide | 1 | 2013 | 14 | 0.460 |
Why?
|
| Adolescent | 26 | 2020 | 2279 | 0.460 |
Why?
|
| Diagnosis, Differential | 16 | 2007 | 389 | 0.460 |
Why?
|
| Neurodegenerative Diseases | 4 | 2012 | 117 | 0.450 |
Why?
|
| Neurosurgical Procedures | 4 | 2012 | 150 | 0.450 |
Why?
|
| Contrast Sensitivity | 3 | 2002 | 8 | 0.450 |
Why?
|
| Dystonic Disorders | 3 | 2021 | 29 | 0.440 |
Why?
|
| Polymorphism, Genetic | 5 | 2007 | 78 | 0.440 |
Why?
|
| Muscle Stretching Exercises | 1 | 2012 | 4 | 0.440 |
Why?
|
| Resistance Training | 1 | 2012 | 8 | 0.440 |
Why?
|
| Tai Ji | 1 | 2012 | 10 | 0.430 |
Why?
|
| Inosine | 4 | 2022 | 5 | 0.430 |
Why?
|
| Weights and Measures | 2 | 2011 | 8 | 0.430 |
Why?
|
| Child | 20 | 2020 | 1346 | 0.430 |
Why?
|
| Attitude of Health Personnel | 2 | 2018 | 148 | 0.420 |
Why?
|
| Disease Management | 1 | 2013 | 114 | 0.420 |
Why?
|
| Prevalence | 8 | 2010 | 487 | 0.420 |
Why?
|
| Paris | 5 | 2017 | 5 | 0.410 |
Why?
|
| Receptors, Dopamine | 13 | 2001 | 30 | 0.410 |
Why?
|
| Pain | 4 | 2021 | 391 | 0.410 |
Why?
|
| Pergolide | 11 | 2005 | 14 | 0.410 |
Why?
|
| Analysis of Variance | 10 | 2013 | 321 | 0.410 |
Why?
|
| Color Vision Defects | 2 | 2002 | 3 | 0.410 |
Why?
|
| Enzyme Inhibitors | 4 | 2002 | 145 | 0.400 |
Why?
|
| Case-Control Studies | 10 | 2014 | 638 | 0.400 |
Why?
|
| Catechol O-Methyltransferase Inhibitors | 3 | 2005 | 5 | 0.400 |
Why?
|
| Benzophenones | 3 | 2005 | 27 | 0.390 |
Why?
|
| Anxiety | 2 | 2010 | 152 | 0.390 |
Why?
|
| Carbazoles | 1 | 2010 | 6 | 0.390 |
Why?
|
| Basal Ganglia | 8 | 2013 | 29 | 0.390 |
Why?
|
| Publishing | 2 | 2008 | 38 | 0.380 |
Why?
|
| Video Recording | 6 | 2020 | 47 | 0.380 |
Why?
|
| Editorial Policies | 2 | 2007 | 7 | 0.380 |
Why?
|
| Bromocriptine | 9 | 2005 | 15 | 0.380 |
Why?
|
| Mercury Compounds | 1 | 2010 | 1 | 0.380 |
Why?
|
| Authorship | 2 | 2007 | 16 | 0.380 |
Why?
|
| Databases, Factual | 4 | 2022 | 330 | 0.380 |
Why?
|
| Botulinum Toxins | 4 | 1997 | 32 | 0.380 |
Why?
|
| Hospitals, Urban | 1 | 2010 | 35 | 0.370 |
Why?
|
| Guidelines as Topic | 4 | 2013 | 67 | 0.370 |
Why?
|
| Treatment Outcome | 16 | 2019 | 3478 | 0.370 |
Why?
|
| Neuroanatomy | 1 | 2010 | 2 | 0.370 |
Why?
|
| Deglutition Disorders | 3 | 2009 | 44 | 0.370 |
Why?
|
| Diagnostic Techniques, Neurological | 2 | 2007 | 10 | 0.370 |
Why?
|
| Medicine in Literature | 2 | 2006 | 3 | 0.370 |
Why?
|
| Microbiology | 1 | 2009 | 2 | 0.360 |
Why?
|
| Tics | 2 | 2008 | 3 | 0.360 |
Why?
|
| Parkinson Disease, Secondary | 9 | 2000 | 29 | 0.360 |
Why?
|
| Lewy Body Disease | 5 | 2016 | 98 | 0.360 |
Why?
|
| Age of Onset | 8 | 2004 | 108 | 0.360 |
Why?
|
| Cognitive Dysfunction | 3 | 2014 | 938 | 0.360 |
Why?
|
| Motion Pictures | 2 | 2006 | 4 | 0.360 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 3 | 2023 | 34 | 0.360 |
Why?
|
| Risk Factors | 18 | 2010 | 2443 | 0.360 |
Why?
|
| Biomarkers | 10 | 2021 | 689 | 0.350 |
Why?
|
| Predictive Value of Tests | 10 | 2013 | 521 | 0.350 |
Why?
|
| Primary Dysautonomias | 1 | 2009 | 5 | 0.350 |
Why?
|
| Muscle Rigidity | 2 | 2007 | 26 | 0.350 |
Why?
|
| REM Sleep Behavior Disorder | 2 | 2008 | 5 | 0.350 |
Why?
|
| Consensus | 2 | 2023 | 105 | 0.350 |
Why?
|
| Metabolic Diseases | 1 | 2009 | 14 | 0.350 |
Why?
|
| Clozapine | 4 | 2011 | 10 | 0.350 |
Why?
|
| Hypokinesia | 1 | 2009 | 27 | 0.350 |
Why?
|
| Communicable Diseases | 1 | 2009 | 24 | 0.340 |
Why?
|
| Age Factors | 11 | 2017 | 843 | 0.340 |
Why?
|
| Aphasia | 2 | 2000 | 9 | 0.330 |
Why?
|
| Drug Monitoring | 1 | 2008 | 24 | 0.330 |
Why?
|
| Tauopathies | 1 | 2008 | 17 | 0.330 |
Why?
|
| Autoimmune Diseases | 1 | 2009 | 61 | 0.330 |
Why?
|
| Nursing Homes | 4 | 2005 | 38 | 0.330 |
Why?
|
| Brief Psychiatric Rating Scale | 1 | 2008 | 8 | 0.330 |
Why?
|
| Disclosure | 2 | 2007 | 16 | 0.330 |
Why?
|
| Benzothiazoles | 6 | 2011 | 20 | 0.330 |
Why?
|
| Memory Disorders | 5 | 2014 | 174 | 0.320 |
Why?
|
| Documentation | 1 | 2008 | 31 | 0.320 |
Why?
|
| Chi-Square Distribution | 4 | 2014 | 145 | 0.320 |
Why?
|
| Essential Tremor | 3 | 2013 | 15 | 0.320 |
Why?
|
| Motivation | 1 | 2008 | 100 | 0.320 |
Why?
|
| Work | 1 | 2007 | 10 | 0.320 |
Why?
|
| Ergolines | 9 | 2005 | 14 | 0.310 |
Why?
|
| Malingering | 1 | 2007 | 1 | 0.310 |
Why?
|
| Neoplasms | 1 | 2010 | 247 | 0.310 |
Why?
|
| Conversion Disorder | 1 | 2007 | 5 | 0.310 |
Why?
|
| United States Agency for Healthcare Research and Quality | 1 | 2007 | 2 | 0.310 |
Why?
|
| Anxiety Disorders | 1 | 2008 | 168 | 0.310 |
Why?
|
| Brain Mapping | 5 | 2005 | 195 | 0.300 |
Why?
|
| Education | 1 | 2007 | 39 | 0.300 |
Why?
|
| Confidentiality | 1 | 2007 | 11 | 0.300 |
Why?
|
| Speech Disorders | 3 | 2003 | 13 | 0.300 |
Why?
|
| Cerebrospinal Fluid Shunts | 2 | 2005 | 8 | 0.300 |
Why?
|
| Prospective Studies | 11 | 2020 | 1811 | 0.300 |
Why?
|
| Communication | 1 | 2008 | 111 | 0.290 |
Why?
|
| Electric Stimulation Therapy | 3 | 2000 | 44 | 0.290 |
Why?
|
| Mesencephalon | 6 | 2017 | 44 | 0.290 |
Why?
|
| Neurophysiology | 2 | 2007 | 3 | 0.290 |
Why?
|
| Point Mutation | 2 | 2003 | 30 | 0.290 |
Why?
|
| Confusion | 1 | 2006 | 14 | 0.290 |
Why?
|
| Depressive Disorder, Major | 1 | 2007 | 107 | 0.290 |
Why?
|
| Child, Preschool | 9 | 2020 | 642 | 0.290 |
Why?
|
| Disorders of Excessive Somnolence | 1 | 2006 | 15 | 0.290 |
Why?
|
| Apomorphine | 16 | 2005 | 37 | 0.290 |
Why?
|
| Seasons | 1 | 2006 | 31 | 0.280 |
Why?
|
| Literature, Modern | 1 | 2006 | 2 | 0.280 |
Why?
|
| Psychophysiologic Disorders | 1 | 2005 | 8 | 0.280 |
Why?
|
| Hypoxia, Brain | 3 | 2001 | 14 | 0.280 |
Why?
|
| Skin Temperature | 1 | 2005 | 2 | 0.270 |
Why?
|
| Thermography | 1 | 2005 | 12 | 0.270 |
Why?
|
| Caudate Nucleus | 7 | 2004 | 18 | 0.270 |
Why?
|
| Observer Variation | 8 | 2011 | 118 | 0.270 |
Why?
|
| Amyotrophic Lateral Sclerosis | 2 | 2010 | 22 | 0.270 |
Why?
|
| Spain | 6 | 2005 | 18 | 0.270 |
Why?
|
| Psychotherapy | 1 | 2005 | 34 | 0.270 |
Why?
|
| Mental Disorders | 4 | 2011 | 140 | 0.270 |
Why?
|
| Terminology as Topic | 4 | 2017 | 48 | 0.270 |
Why?
|
| Hydrocephalus | 1 | 2005 | 25 | 0.270 |
Why?
|
| Regression Analysis | 5 | 2018 | 298 | 0.270 |
Why?
|
| Feasibility Studies | 5 | 2013 | 227 | 0.270 |
Why?
|
| Retrospective Studies | 11 | 2021 | 3273 | 0.270 |
Why?
|
| Posture | 8 | 2021 | 78 | 0.260 |
Why?
|
| Mentors | 2 | 2022 | 47 | 0.260 |
Why?
|
| Frontal Lobe | 3 | 2005 | 81 | 0.260 |
Why?
|
| Dosage Compensation, Genetic | 1 | 2005 | 2 | 0.260 |
Why?
|
| Chromosomes, Human, X | 1 | 2005 | 9 | 0.260 |
Why?
|
| Time | 1 | 2005 | 18 | 0.260 |
Why?
|
| Siblings | 1 | 2005 | 18 | 0.260 |
Why?
|
| Advisory Committees | 4 | 2014 | 34 | 0.260 |
Why?
|
| Drug Combinations | 15 | 2009 | 82 | 0.260 |
Why?
|
| Indoles | 2 | 2005 | 48 | 0.260 |
Why?
|
| Postoperative Care | 1 | 2005 | 127 | 0.260 |
Why?
|
| Atrophy | 8 | 2014 | 102 | 0.250 |
Why?
|
| Aging | 2 | 2008 | 1593 | 0.250 |
Why?
|
| Memory | 4 | 2013 | 318 | 0.250 |
Why?
|
| Serotonin | 6 | 2000 | 40 | 0.250 |
Why?
|
| Drug Therapy, Combination | 9 | 2006 | 241 | 0.250 |
Why?
|
| Space Perception | 2 | 2014 | 28 | 0.250 |
Why?
|
| Certification | 1 | 2004 | 49 | 0.250 |
Why?
|
| Mitochondria | 3 | 2020 | 78 | 0.250 |
Why?
|
| Basal Ganglia Diseases | 3 | 2000 | 11 | 0.250 |
Why?
|
| Adrenal Glands | 3 | 2000 | 8 | 0.250 |
Why?
|
| Neurons | 7 | 2020 | 374 | 0.250 |
Why?
|
| Apolipoproteins E | 3 | 2004 | 230 | 0.250 |
Why?
|
| Single-Blind Method | 4 | 2008 | 118 | 0.240 |
Why?
|
| Walkers | 1 | 2003 | 2 | 0.240 |
Why?
|
| Europe | 6 | 2006 | 81 | 0.240 |
Why?
|
| Paraneoplastic Syndromes | 2 | 2001 | 8 | 0.240 |
Why?
|
| Neck | 3 | 2020 | 33 | 0.240 |
Why?
|
| United Kingdom | 4 | 2018 | 50 | 0.240 |
Why?
|
| Sick Role | 1 | 2003 | 12 | 0.240 |
Why?
|
| Fragile X Mental Retardation Protein | 4 | 2009 | 117 | 0.240 |
Why?
|
| Practice Guidelines as Topic | 2 | 2016 | 333 | 0.230 |
Why?
|
| Stereotyped Behavior | 12 | 1988 | 30 | 0.230 |
Why?
|
| Genotype | 9 | 2011 | 405 | 0.230 |
Why?
|
| Piperazines | 5 | 2011 | 90 | 0.230 |
Why?
|
| Reflex, Babinski | 1 | 2002 | 1 | 0.230 |
Why?
|
| Osteoarthritis, Knee | 2 | 2020 | 381 | 0.230 |
Why?
|
| Brain Tissue Transplantation | 7 | 2017 | 25 | 0.230 |
Why?
|
| Physicians, Women | 2 | 2002 | 18 | 0.230 |
Why?
|
| Drug Administration Schedule | 8 | 2009 | 223 | 0.230 |
Why?
|
| Genetic Variation | 2 | 2001 | 105 | 0.230 |
Why?
|
| Statistics, Nonparametric | 5 | 2018 | 138 | 0.220 |
Why?
|
| Ubiquitin-Protein Ligases | 4 | 2003 | 36 | 0.220 |
Why?
|
| History, 18th Century | 2 | 2018 | 8 | 0.220 |
Why?
|
| Clonidine | 4 | 1992 | 31 | 0.220 |
Why?
|
| Neurosecretory Systems | 1 | 2022 | 9 | 0.220 |
Why?
|
| Dominance, Cerebral | 2 | 2000 | 23 | 0.220 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2022 | 11 | 0.220 |
Why?
|
| Adaptation, Psychological | 1 | 2003 | 143 | 0.220 |
Why?
|
| Electromyography | 3 | 1998 | 78 | 0.220 |
Why?
|
| Loneliness | 1 | 2022 | 52 | 0.210 |
Why?
|
| Correspondence as Topic | 1 | 2001 | 1 | 0.210 |
Why?
|
| Incidence | 4 | 2010 | 756 | 0.210 |
Why?
|
| Registries | 3 | 1996 | 188 | 0.210 |
Why?
|
| Hyperkinesis | 2 | 1998 | 11 | 0.210 |
Why?
|
| Peer Group | 1 | 2022 | 40 | 0.210 |
Why?
|
| Odds Ratio | 3 | 2008 | 285 | 0.210 |
Why?
|
| Office Visits | 1 | 2021 | 12 | 0.200 |
Why?
|
| Syndrome | 6 | 2006 | 82 | 0.200 |
Why?
|
| Warfare | 2 | 2007 | 14 | 0.200 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2001 | 35 | 0.200 |
Why?
|
| Mental Status Schedule | 3 | 2013 | 113 | 0.200 |
Why?
|
| Sjogren-Larsson Syndrome | 1 | 2000 | 1 | 0.200 |
Why?
|
| Dental Care for Disabled | 1 | 2020 | 1 | 0.200 |
Why?
|
| Dental Instruments | 1 | 2020 | 1 | 0.200 |
Why?
|
| Diagnosis, Oral | 1 | 2020 | 1 | 0.200 |
Why?
|
| Menstrual Cycle | 1 | 2000 | 27 | 0.200 |
Why?
|
| Pirenzepine | 1 | 2000 | 6 | 0.200 |
Why?
|
| Axons | 2 | 2020 | 38 | 0.190 |
Why?
|
| Kidney Neoplasms | 1 | 2001 | 60 | 0.190 |
Why?
|
| Toxins, Biological | 1 | 2000 | 1 | 0.190 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2000 | 4 | 0.190 |
Why?
|
| Haloperidol | 11 | 1990 | 31 | 0.190 |
Why?
|
| PubMed | 3 | 2011 | 12 | 0.190 |
Why?
|
| Pyridines | 2 | 2016 | 42 | 0.190 |
Why?
|
| Linear Models | 3 | 2020 | 254 | 0.190 |
Why?
|
| Data Interpretation, Statistical | 3 | 2009 | 96 | 0.190 |
Why?
|
| Ventral Thalamic Nuclei | 1 | 2000 | 3 | 0.190 |
Why?
|
| alpha-Synuclein | 4 | 2017 | 138 | 0.190 |
Why?
|
| Genetic Predisposition to Disease | 9 | 2007 | 441 | 0.190 |
Why?
|
| Nose Diseases | 1 | 2020 | 8 | 0.190 |
Why?
|
| Evidence-Based Medicine | 2 | 2011 | 208 | 0.190 |
Why?
|
| Epilepsies, Myoclonic | 1 | 2000 | 4 | 0.190 |
Why?
|
| Health Status | 4 | 2013 | 227 | 0.190 |
Why?
|
| Ligases | 4 | 2003 | 7 | 0.190 |
Why?
|
| Lewy Bodies | 4 | 2014 | 195 | 0.180 |
Why?
|
| Neck Muscles | 2 | 1998 | 13 | 0.180 |
Why?
|
| Prognosis | 6 | 2021 | 840 | 0.180 |
Why?
|
| Head | 1 | 2020 | 24 | 0.180 |
Why?
|
| Neurosciences | 1 | 1999 | 10 | 0.180 |
Why?
|
| Putamen | 3 | 2015 | 23 | 0.180 |
Why?
|
| Sample Size | 2 | 2013 | 25 | 0.180 |
Why?
|
| Brain Diseases | 3 | 1998 | 82 | 0.180 |
Why?
|
| Selegiline | 4 | 2005 | 6 | 0.180 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2006 | 31 | 0.180 |
Why?
|
| Thalamus | 5 | 2011 | 28 | 0.180 |
Why?
|
| Impulsive Behavior | 1 | 2019 | 21 | 0.170 |
Why?
|
| Organic Chemicals | 3 | 2008 | 8 | 0.170 |
Why?
|
| Reference Standards | 3 | 2020 | 33 | 0.170 |
Why?
|
| Fluphenazine | 5 | 1986 | 8 | 0.170 |
Why?
|
| Visual Perception | 3 | 2005 | 50 | 0.170 |
Why?
|
| Biological Evolution | 1 | 2019 | 23 | 0.170 |
Why?
|
| Mobile Applications | 1 | 2019 | 24 | 0.170 |
Why?
|
| Antidepressive Agents | 4 | 2005 | 100 | 0.170 |
Why?
|
| Betacoronavirus | 1 | 2020 | 75 | 0.170 |
Why?
|
| Attention | 4 | 2014 | 144 | 0.170 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2018 | 6 | 0.170 |
Why?
|
| Disabled Persons | 1 | 2020 | 127 | 0.170 |
Why?
|
| Patient Outcome Assessment | 1 | 2019 | 43 | 0.170 |
Why?
|
| Polypharmacy | 1 | 1998 | 10 | 0.170 |
Why?
|
| Muscle Spasticity | 3 | 1997 | 16 | 0.170 |
Why?
|
| Wearable Electronic Devices | 1 | 2019 | 40 | 0.170 |
Why?
|
| Nerve Tissue Proteins | 4 | 2005 | 173 | 0.170 |
Why?
|
| Corneal Stroma | 1 | 2018 | 1 | 0.170 |
Why?
|
| Riboflavin | 1 | 2018 | 1 | 0.170 |
Why?
|
| Keratoconus | 1 | 2018 | 2 | 0.170 |
Why?
|
| Memory, Short-Term | 1 | 1999 | 102 | 0.170 |
Why?
|
| Photosensitizing Agents | 1 | 2018 | 5 | 0.170 |
Why?
|
| Photochemotherapy | 1 | 2018 | 5 | 0.170 |
Why?
|
| Head Movements | 1 | 1998 | 7 | 0.160 |
Why?
|
| Gene Frequency | 5 | 2011 | 75 | 0.160 |
Why?
|
| Cross-Linking Reagents | 1 | 2018 | 15 | 0.160 |
Why?
|
| Sex Characteristics | 1 | 2019 | 132 | 0.160 |
Why?
|
| Transplantation, Heterotopic | 4 | 1997 | 12 | 0.160 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 86 | 0.160 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 89 | 0.160 |
Why?
|
| Fuchs' Endothelial Dystrophy | 1 | 2017 | 2 | 0.160 |
Why?
|
| Corneal Diseases | 1 | 2017 | 3 | 0.160 |
Why?
|
| Descemet Stripping Endothelial Keratoplasty | 1 | 2017 | 3 | 0.160 |
Why?
|
| Ocular Motility Disorders | 1 | 1997 | 3 | 0.160 |
Why?
|
| Faculty, Medical | 2 | 1996 | 38 | 0.160 |
Why?
|
| Keratoplasty, Penetrating | 1 | 2017 | 6 | 0.160 |
Why?
|
| Executive Function | 3 | 2014 | 121 | 0.160 |
Why?
|
| Pandemics | 1 | 2020 | 236 | 0.160 |
Why?
|
| Mass Screening | 3 | 2018 | 177 | 0.160 |
Why?
|
| Tibia | 1 | 2020 | 259 | 0.160 |
Why?
|
| Motor Activity | 9 | 2011 | 369 | 0.160 |
Why?
|
| Seveso Accidental Release | 1 | 2017 | 2 | 0.160 |
Why?
|
| Chronic Disease | 6 | 2010 | 495 | 0.150 |
Why?
|
| Cell Transplantation | 3 | 2009 | 29 | 0.150 |
Why?
|
| Checklist | 2 | 2022 | 36 | 0.150 |
Why?
|
| Dissociative Disorders | 1 | 1997 | 4 | 0.150 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 1997 | 11 | 0.150 |
Why?
|
| Thioridazine | 3 | 1986 | 9 | 0.150 |
Why?
|
| Nitrophenols | 3 | 2005 | 4 | 0.150 |
Why?
|
| Comorbidity | 3 | 2010 | 498 | 0.150 |
Why?
|
| Research | 2 | 2007 | 54 | 0.150 |
Why?
|
| Program Evaluation | 2 | 2010 | 132 | 0.150 |
Why?
|
| Graft Survival | 1 | 2017 | 98 | 0.140 |
Why?
|
| Learning | 1 | 1997 | 79 | 0.140 |
Why?
|
| Receptor, Metabotropic Glutamate 5 | 1 | 2016 | 15 | 0.140 |
Why?
|
| Serotonin Antagonists | 5 | 2000 | 19 | 0.140 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2016 | 4 | 0.140 |
Why?
|
| Alleles | 7 | 2009 | 224 | 0.140 |
Why?
|
| Drug Interactions | 6 | 2002 | 67 | 0.140 |
Why?
|
| Dopaminergic Neurons | 1 | 2017 | 44 | 0.140 |
Why?
|
| Caregivers | 1 | 2018 | 143 | 0.140 |
Why?
|
| Phylogeny | 1 | 2015 | 63 | 0.140 |
Why?
|
| Imidazoles | 1 | 2016 | 72 | 0.140 |
Why?
|
| Textbooks as Topic | 1 | 1995 | 3 | 0.140 |
Why?
|
| Axonal Transport | 1 | 2015 | 8 | 0.130 |
Why?
|
| Prodromal Symptoms | 1 | 2015 | 19 | 0.130 |
Why?
|
| Audiovisual Aids | 1 | 1995 | 3 | 0.130 |
Why?
|
| Reference Values | 4 | 2006 | 227 | 0.130 |
Why?
|
| Hydrocephalus, Normal Pressure | 1 | 2015 | 1 | 0.130 |
Why?
|
| Self Care | 2 | 2008 | 90 | 0.130 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 379 | 0.130 |
Why?
|
| Cartilage, Articular | 1 | 2020 | 524 | 0.130 |
Why?
|
| Genetic Vectors | 1 | 2015 | 60 | 0.130 |
Why?
|
| Neurturin | 1 | 2015 | 24 | 0.130 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2015 | 10 | 0.130 |
Why?
|
| ROC Curve | 4 | 2020 | 138 | 0.130 |
Why?
|
| Obsessive-Compulsive Disorder | 2 | 2009 | 23 | 0.130 |
Why?
|
| Translations | 3 | 2021 | 16 | 0.130 |
Why?
|
| Young Adult | 4 | 2020 | 1932 | 0.130 |
Why?
|
| Cerebellum | 3 | 2013 | 57 | 0.130 |
Why?
|
| Polychlorinated Dibenzodioxins | 1 | 1994 | 1 | 0.130 |
Why?
|
| 2,4-Dichlorophenoxyacetic Acid | 1 | 1994 | 1 | 0.130 |
Why?
|
| 2,4,5-Trichlorophenoxyacetic Acid | 1 | 1994 | 1 | 0.130 |
Why?
|
| Socioeconomic Factors | 2 | 2013 | 328 | 0.130 |
Why?
|
| Superior Colliculi | 1 | 2014 | 2 | 0.130 |
Why?
|
| Azepines | 1 | 1994 | 6 | 0.130 |
Why?
|
| Genetic Therapy | 1 | 2015 | 89 | 0.130 |
Why?
|
| Germany | 2 | 2006 | 11 | 0.120 |
Why?
|
| Osteoarthritis, Hip | 1 | 2015 | 94 | 0.120 |
Why?
|
| Postal Service | 1 | 2014 | 2 | 0.120 |
Why?
|
| Drug Eruptions | 2 | 1984 | 10 | 0.120 |
Why?
|
| Institutionalization | 1 | 1993 | 3 | 0.120 |
Why?
|
| Clonazepam | 3 | 1992 | 29 | 0.120 |
Why?
|
| Knee Joint | 1 | 2020 | 797 | 0.120 |
Why?
|
| Sleep | 4 | 2013 | 313 | 0.120 |
Why?
|
| Monitoring, Ambulatory | 1 | 2013 | 19 | 0.120 |
Why?
|
| Functional Neuroimaging | 1 | 2013 | 9 | 0.120 |
Why?
|
| Interviews as Topic | 1 | 2014 | 130 | 0.120 |
Why?
|
| Schools, Medical | 2 | 1996 | 22 | 0.120 |
Why?
|
| New York City | 1 | 2013 | 18 | 0.120 |
Why?
|
| Behavior, Animal | 6 | 1991 | 105 | 0.120 |
Why?
|
| Rats | 10 | 2001 | 854 | 0.120 |
Why?
|
| Postoperative Complications | 6 | 2017 | 957 | 0.120 |
Why?
|
| Muscles | 1 | 1993 | 72 | 0.110 |
Why?
|
| Spouses | 1 | 2013 | 25 | 0.110 |
Why?
|
| Sensation Disorders | 1 | 2013 | 13 | 0.110 |
Why?
|
| Constipation | 2 | 2011 | 21 | 0.110 |
Why?
|
| Biomechanical Phenomena | 4 | 2013 | 668 | 0.110 |
Why?
|
| Cost of Illness | 1 | 2013 | 54 | 0.110 |
Why?
|
| Accelerometry | 1 | 2013 | 87 | 0.110 |
Why?
|
| Head Injuries, Closed | 1 | 1992 | 1 | 0.110 |
Why?
|
| Imagination | 1 | 1992 | 4 | 0.110 |
Why?
|
| Orientation | 1 | 1992 | 10 | 0.110 |
Why?
|
| Concept Formation | 1 | 1992 | 11 | 0.110 |
Why?
|
| Thinking | 1 | 1992 | 15 | 0.110 |
Why?
|
| Cost-Benefit Analysis | 1 | 2013 | 144 | 0.110 |
Why?
|
| Brain Concussion | 1 | 1992 | 14 | 0.110 |
Why?
|
| Hand Strength | 1 | 2013 | 59 | 0.110 |
Why?
|
| Pattern Recognition, Visual | 1 | 1992 | 31 | 0.110 |
Why?
|
| Parasympatholytics | 8 | 1990 | 14 | 0.110 |
Why?
|
| Observation | 1 | 2012 | 16 | 0.110 |
Why?
|
| Calibration | 1 | 2012 | 22 | 0.110 |
Why?
|
| Nontherapeutic Human Experimentation | 1 | 2012 | 1 | 0.110 |
Why?
|
| Functional Laterality | 5 | 2003 | 91 | 0.110 |
Why?
|
| Problem Solving | 1 | 1992 | 45 | 0.110 |
Why?
|
| Guinea Pigs | 15 | 1998 | 63 | 0.110 |
Why?
|
| Amnesia | 1 | 2012 | 27 | 0.110 |
Why?
|
| Disease Models, Animal | 8 | 2011 | 724 | 0.110 |
Why?
|
| Patient Satisfaction | 2 | 2020 | 295 | 0.110 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2013 | 219 | 0.110 |
Why?
|
| Entorhinal Cortex | 1 | 2012 | 37 | 0.110 |
Why?
|
| Ethics, Medical | 2 | 2003 | 17 | 0.100 |
Why?
|
| Autonomic Nervous System Diseases | 3 | 2011 | 27 | 0.100 |
Why?
|
| Dysbiosis | 2 | 2022 | 64 | 0.100 |
Why?
|
| Benzoxazoles | 1 | 2011 | 2 | 0.100 |
Why?
|
| Peripheral Nervous System Diseases | 2 | 2007 | 33 | 0.100 |
Why?
|
| Autonomic Nervous System | 3 | 1998 | 23 | 0.100 |
Why?
|
| Multicenter Studies as Topic | 2 | 2008 | 75 | 0.100 |
Why?
|
| Light | 2 | 2006 | 76 | 0.100 |
Why?
|
| Nerve Compression Syndromes | 2 | 1982 | 26 | 0.100 |
Why?
|
| Area Under Curve | 2 | 2020 | 66 | 0.100 |
Why?
|
| Accidents, Traffic | 1 | 1991 | 14 | 0.100 |
Why?
|
| Journal Impact Factor | 1 | 2011 | 15 | 0.100 |
Why?
|
| Pedigree | 4 | 2009 | 77 | 0.100 |
Why?
|
| Craniocerebral Trauma | 1 | 1991 | 11 | 0.100 |
Why?
|
| Prefrontal Cortex | 1 | 1992 | 152 | 0.100 |
Why?
|
| Lisuride | 3 | 2005 | 4 | 0.100 |
Why?
|
| Drug Delivery Systems | 1 | 2011 | 37 | 0.100 |
Why?
|
| Poland | 2 | 2021 | 6 | 0.100 |
Why?
|
| Receptors, Serotonin | 3 | 2000 | 21 | 0.100 |
Why?
|
| Estrogens | 2 | 2001 | 33 | 0.100 |
Why?
|
| Genetic Association Studies | 1 | 2011 | 86 | 0.100 |
Why?
|
| Trinucleotide Repeat Expansion | 2 | 2007 | 47 | 0.100 |
Why?
|
| Polysomnography | 1 | 2010 | 92 | 0.100 |
Why?
|
| Survivors | 1 | 2010 | 57 | 0.100 |
Why?
|
| Self Report | 1 | 2011 | 218 | 0.090 |
Why?
|
| Task Performance and Analysis | 3 | 2007 | 55 | 0.090 |
Why?
|
| Risk Assessment | 3 | 2003 | 679 | 0.090 |
Why?
|
| Transplantation, Autologous | 7 | 1997 | 195 | 0.090 |
Why?
|
| Benzodiazepines | 2 | 2000 | 60 | 0.090 |
Why?
|
| Delusions | 2 | 2008 | 12 | 0.090 |
Why?
|
| Diseases in Twins | 1 | 1990 | 8 | 0.090 |
Why?
|
| Body Weight | 1 | 2010 | 133 | 0.090 |
Why?
|
| Neuromuscular Diseases | 2 | 1990 | 9 | 0.090 |
Why?
|
| Illinois | 1 | 2010 | 241 | 0.090 |
Why?
|
| Neurotransmitter Agents | 2 | 2009 | 20 | 0.090 |
Why?
|
| Head Protective Devices | 1 | 2009 | 3 | 0.090 |
Why?
|
| Algorithms | 1 | 2012 | 400 | 0.090 |
Why?
|
| Delayed-Action Preparations | 5 | 1991 | 38 | 0.090 |
Why?
|
| Illusions | 1 | 2009 | 4 | 0.090 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2009 | 16 | 0.090 |
Why?
|
| Interprofessional Relations | 1 | 2009 | 34 | 0.090 |
Why?
|
| Sialorrhea | 1 | 2009 | 5 | 0.090 |
Why?
|
| Confidence Intervals | 1 | 2009 | 96 | 0.090 |
Why?
|
| Fibroblasts | 1 | 2009 | 95 | 0.090 |
Why?
|
| Israel | 2 | 2020 | 16 | 0.090 |
Why?
|
| Logistic Models | 3 | 2013 | 407 | 0.090 |
Why?
|
| Computer-Aided Design | 1 | 2009 | 16 | 0.090 |
Why?
|
| Epilepsy, Temporal Lobe | 1 | 1989 | 46 | 0.090 |
Why?
|
| Multiple Sclerosis | 1 | 2010 | 87 | 0.090 |
Why?
|
| Brain Chemistry | 3 | 2005 | 47 | 0.090 |
Why?
|
| Aluminum | 1 | 1988 | 11 | 0.090 |
Why?
|
| Proportional Hazards Models | 2 | 2008 | 340 | 0.080 |
Why?
|
| Opioid Peptides | 1 | 2008 | 6 | 0.080 |
Why?
|
| Exercise | 1 | 1993 | 468 | 0.080 |
Why?
|
| Meta-Analysis as Topic | 1 | 2008 | 41 | 0.080 |
Why?
|
| Genetic Carrier Screening | 2 | 2007 | 12 | 0.080 |
Why?
|
| Parietal Lobe | 2 | 2005 | 21 | 0.080 |
Why?
|
| Subacute Sclerosing Panencephalitis | 1 | 1988 | 1 | 0.080 |
Why?
|
| Swine | 1 | 2008 | 80 | 0.080 |
Why?
|
| Positron-Emission Tomography | 1 | 2008 | 88 | 0.080 |
Why?
|
| Apolipoprotein E4 | 2 | 2007 | 227 | 0.080 |
Why?
|
| Catalepsy | 1 | 2007 | 1 | 0.080 |
Why?
|
| Neurasthenia | 1 | 2007 | 1 | 0.080 |
Why?
|
| Deception | 1 | 2007 | 2 | 0.080 |
Why?
|
| Philadelphia | 1 | 2007 | 5 | 0.080 |
Why?
|
| Hospitals, Military | 1 | 2007 | 5 | 0.080 |
Why?
|
| National Institute of Mental Health (U.S.) | 1 | 2007 | 5 | 0.080 |
Why?
|
| Automatism | 1 | 1987 | 1 | 0.080 |
Why?
|
| Review Literature as Topic | 1 | 2007 | 10 | 0.080 |
Why?
|
| Hospitals, Psychiatric | 1 | 2007 | 15 | 0.080 |
Why?
|
| Military Medicine | 1 | 2007 | 14 | 0.080 |
Why?
|
| Renal Dialysis | 1 | 1988 | 113 | 0.080 |
Why?
|
| Sex Factors | 4 | 2007 | 496 | 0.080 |
Why?
|
| Contracture | 1 | 2007 | 13 | 0.080 |
Why?
|
| Motor Neurons | 2 | 1998 | 21 | 0.080 |
Why?
|
| Military Personnel | 1 | 2007 | 34 | 0.080 |
Why?
|
| Physician-Patient Relations | 1 | 2007 | 39 | 0.080 |
Why?
|
| Serotonin Receptor Agonists | 1 | 2007 | 9 | 0.080 |
Why?
|
| Intellectual Disability | 1 | 1988 | 48 | 0.080 |
Why?
|
| Spinal Cord | 1 | 1988 | 103 | 0.070 |
Why?
|
| Periodicals as Topic | 1 | 2007 | 41 | 0.070 |
Why?
|
| Acoustic Stimulation | 2 | 2004 | 47 | 0.070 |
Why?
|
| Hospitals | 1 | 1988 | 157 | 0.070 |
Why?
|
| Quinolones | 1 | 2006 | 21 | 0.070 |
Why?
|
| Akathisia, Drug-Induced | 2 | 1998 | 4 | 0.070 |
Why?
|
| Cross-Cultural Comparison | 2 | 2023 | 42 | 0.070 |
Why?
|
| Diagnostic Errors | 4 | 2003 | 40 | 0.070 |
Why?
|
| Psychomotor Agitation | 2 | 1998 | 14 | 0.070 |
Why?
|
| Patient Selection | 2 | 2009 | 232 | 0.070 |
Why?
|
| DNA Mutational Analysis | 2 | 2003 | 56 | 0.070 |
Why?
|
| Organ Size | 2 | 2020 | 107 | 0.070 |
Why?
|
| Combined Modality Therapy | 4 | 2005 | 364 | 0.070 |
Why?
|
| Darkness | 1 | 2006 | 18 | 0.070 |
Why?
|
| History, 17th Century | 2 | 2001 | 2 | 0.070 |
Why?
|
| Models, Biological | 2 | 2005 | 343 | 0.070 |
Why?
|
| Parkinson Disease, Postencephalitic | 1 | 2006 | 1 | 0.070 |
Why?
|
| Interview, Psychological | 1 | 2006 | 36 | 0.070 |
Why?
|
| Epilepsy | 1 | 1987 | 104 | 0.070 |
Why?
|
| Vitamin E | 2 | 1996 | 27 | 0.070 |
Why?
|
| Brain Neoplasms | 2 | 2005 | 124 | 0.070 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 2 | 2021 | 12 | 0.070 |
Why?
|
| Somatoform Disorders | 1 | 2005 | 20 | 0.070 |
Why?
|
| Anti-Anxiety Agents | 1 | 2005 | 38 | 0.070 |
Why?
|
| Cerebrospinal Fluid Pressure | 1 | 2005 | 4 | 0.070 |
Why?
|
| Tyrosine 3-Monooxygenase | 3 | 2017 | 83 | 0.070 |
Why?
|
| Prodrugs | 2 | 2006 | 4 | 0.070 |
Why?
|
| Inpatients | 1 | 2007 | 141 | 0.070 |
Why?
|
| Intracranial Hypertension | 1 | 2005 | 14 | 0.070 |
Why?
|
| Piribedil | 1 | 2005 | 1 | 0.070 |
Why?
|
| Neuroectodermal Tumors | 1 | 2005 | 1 | 0.070 |
Why?
|
| Dihydroergocryptine | 1 | 2005 | 1 | 0.070 |
Why?
|
| Cerebellar Nuclei | 1 | 2005 | 2 | 0.070 |
Why?
|
| RNA, Messenger | 2 | 2003 | 323 | 0.070 |
Why?
|
| Occipital Lobe | 1 | 2005 | 13 | 0.070 |
Why?
|
| Disease Outbreaks | 1 | 2006 | 88 | 0.070 |
Why?
|
| Corpus Callosum | 1 | 2005 | 15 | 0.070 |
Why?
|
| Vision Tests | 2 | 2002 | 4 | 0.070 |
Why?
|
| Models, Statistical | 1 | 2006 | 132 | 0.070 |
Why?
|
| Behavior | 3 | 2000 | 27 | 0.070 |
Why?
|
| Nonlinear Dynamics | 1 | 2005 | 14 | 0.070 |
Why?
|
| RNA-Binding Proteins | 1 | 2005 | 22 | 0.070 |
Why?
|
| Propiophenones | 1 | 1984 | 3 | 0.060 |
Why?
|
| Receptors, Cholecystokinin | 1 | 2004 | 3 | 0.060 |
Why?
|
| Somnambulism | 1 | 2004 | 1 | 0.060 |
Why?
|
| Hypnosis | 1 | 2004 | 2 | 0.060 |
Why?
|
| Mental Competency | 1 | 2004 | 8 | 0.060 |
Why?
|
| Expert Testimony | 1 | 2004 | 12 | 0.060 |
Why?
|
| Temporal Lobe | 1 | 2005 | 105 | 0.060 |
Why?
|
| Speech | 2 | 2005 | 27 | 0.060 |
Why?
|
| Cross-Over Studies | 2 | 2009 | 78 | 0.060 |
Why?
|
| Olivary Nucleus | 1 | 1984 | 1 | 0.060 |
Why?
|
| Pons | 1 | 1984 | 6 | 0.060 |
Why?
|
| Cerebellar Ataxia | 1 | 1984 | 6 | 0.060 |
Why?
|
| Coloring Agents | 1 | 1984 | 13 | 0.060 |
Why?
|
| Glutathione Transferase | 1 | 2003 | 6 | 0.060 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2005 | 75 | 0.060 |
Why?
|
| Immobilization | 1 | 2003 | 14 | 0.060 |
Why?
|
| Dihydroxyphenylalanine | 1 | 2003 | 7 | 0.060 |
Why?
|
| DNA Methylation | 1 | 2005 | 124 | 0.060 |
Why?
|
| Workers' Compensation | 1 | 2004 | 59 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2006 | 194 | 0.060 |
Why?
|
| Treatment Failure | 2 | 2021 | 159 | 0.060 |
Why?
|
| Reality Testing | 1 | 2003 | 1 | 0.060 |
Why?
|
| Spasm | 1 | 1983 | 7 | 0.060 |
Why?
|
| Charcot-Marie-Tooth Disease | 1 | 2003 | 2 | 0.060 |
Why?
|
| Alzheimer Disease | 3 | 2003 | 1942 | 0.060 |
Why?
|
| Death, Sudden | 1 | 1983 | 14 | 0.060 |
Why?
|
| Central Nervous System | 2 | 2003 | 57 | 0.060 |
Why?
|
| Acidosis | 1 | 1983 | 7 | 0.060 |
Why?
|
| Arylamine N-Acetyltransferase | 1 | 2003 | 1 | 0.060 |
Why?
|
| Vision Disorders | 2 | 2005 | 23 | 0.060 |
Why?
|
| Life Tables | 1 | 2003 | 5 | 0.060 |
Why?
|
| Acute Disease | 2 | 2000 | 226 | 0.060 |
Why?
|
| DNA, Mitochondrial | 1 | 2003 | 9 | 0.060 |
Why?
|
| Writing | 1 | 2003 | 20 | 0.060 |
Why?
|
| Radiography | 2 | 2020 | 678 | 0.060 |
Why?
|
| Spondylitis, Ankylosing | 1 | 2003 | 44 | 0.060 |
Why?
|
| Tomography, Emission-Computed | 3 | 2003 | 11 | 0.060 |
Why?
|
| Prebiotics | 1 | 2023 | 16 | 0.060 |
Why?
|
| Medicine in the Arts | 1 | 2002 | 2 | 0.060 |
Why?
|
| Pyramidal Tracts | 1 | 2002 | 4 | 0.060 |
Why?
|
| Paintings | 1 | 2002 | 3 | 0.060 |
Why?
|
| Fatty Acids, Volatile | 1 | 2023 | 30 | 0.060 |
Why?
|
| Cholinergic Antagonists | 2 | 2000 | 13 | 0.060 |
Why?
|
| Cause of Death | 1 | 2003 | 65 | 0.060 |
Why?
|
| Haplotypes | 4 | 2003 | 61 | 0.060 |
Why?
|
| 5-Hydroxytryptophan | 5 | 1998 | 12 | 0.060 |
Why?
|
| Feces | 1 | 2023 | 98 | 0.060 |
Why?
|
| Tissue Extracts | 2 | 1993 | 13 | 0.050 |
Why?
|
| Carbon Monoxide Poisoning | 1 | 1982 | 1 | 0.050 |
Why?
|
| Cooperative Behavior | 1 | 2003 | 87 | 0.050 |
Why?
|
| Biological Availability | 1 | 2002 | 26 | 0.050 |
Why?
|
| Butyrates | 1 | 2022 | 19 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2022 | 39 | 0.050 |
Why?
|
| Chromosomes, Human | 1 | 2002 | 7 | 0.050 |
Why?
|
| Tocopherols | 1 | 2002 | 6 | 0.050 |
Why?
|
| Handwriting | 1 | 1982 | 2 | 0.050 |
Why?
|
| Postmenopause | 1 | 2002 | 61 | 0.050 |
Why?
|
| Lactose | 2 | 1992 | 2 | 0.050 |
Why?
|
| Methylcellulose | 2 | 1992 | 3 | 0.050 |
Why?
|
| Walking | 2 | 2005 | 252 | 0.050 |
Why?
|
| Bias | 1 | 2022 | 33 | 0.050 |
Why?
|
| Social Support | 1 | 2003 | 185 | 0.050 |
Why?
|
| Bacteria | 1 | 2022 | 77 | 0.050 |
Why?
|
| Patient Education as Topic | 2 | 2018 | 162 | 0.050 |
Why?
|
| Kidney Calculi | 1 | 2021 | 4 | 0.050 |
Why?
|
| Finland | 1 | 2021 | 6 | 0.050 |
Why?
|
| Administration, Oral | 2 | 1999 | 140 | 0.050 |
Why?
|
| Touch | 1 | 2021 | 11 | 0.050 |
Why?
|
| Forecasting | 4 | 2007 | 117 | 0.050 |
Why?
|
| History, 15th Century | 1 | 2001 | 1 | 0.050 |
Why?
|
| History, Medieval | 1 | 2001 | 1 | 0.050 |
Why?
|
| Creatine Kinase | 1 | 1981 | 33 | 0.050 |
Why?
|
| Infant | 2 | 2020 | 531 | 0.050 |
Why?
|
| England | 1 | 2001 | 12 | 0.050 |
Why?
|
| Tetrahydronaphthalenes | 1 | 2001 | 4 | 0.050 |
Why?
|
| Receptors, Dopamine D1 | 1 | 2001 | 7 | 0.050 |
Why?
|
| Psychiatry | 1 | 2001 | 10 | 0.050 |
Why?
|
| Electronics | 1 | 2021 | 9 | 0.050 |
Why?
|
| Rest | 1 | 2001 | 32 | 0.050 |
Why?
|
| Nerve Growth Factors | 2 | 1999 | 44 | 0.050 |
Why?
|
| Medication Adherence | 1 | 2022 | 78 | 0.050 |
Why?
|
| Progesterone | 1 | 2000 | 26 | 0.050 |
Why?
|
| Dental Anxiety | 1 | 2020 | 2 | 0.050 |
Why?
|
| Mouth | 1 | 2020 | 11 | 0.050 |
Why?
|
| Vaccination | 1 | 2021 | 41 | 0.050 |
Why?
|
| Kinetics | 1 | 2001 | 225 | 0.050 |
Why?
|
| Biopsy | 1 | 2001 | 234 | 0.050 |
Why?
|
| tau Proteins | 1 | 2001 | 202 | 0.050 |
Why?
|
| Austria | 1 | 2020 | 5 | 0.050 |
Why?
|
| Life Style | 1 | 2022 | 211 | 0.050 |
Why?
|
| Propionates | 1 | 2000 | 12 | 0.050 |
Why?
|
| Neurotoxins | 1 | 2000 | 19 | 0.050 |
Why?
|
| Sensory Aids | 1 | 2000 | 3 | 0.050 |
Why?
|
| Phenotype | 3 | 2009 | 355 | 0.050 |
Why?
|
| Fingers | 1 | 2020 | 10 | 0.050 |
Why?
|
| Therapeutic Human Experimentation | 1 | 1999 | 1 | 0.050 |
Why?
|
| Control Groups | 1 | 1999 | 2 | 0.050 |
Why?
|
| Kuru | 1 | 1999 | 2 | 0.050 |
Why?
|
| Cues | 1 | 2000 | 61 | 0.050 |
Why?
|
| Drug Stability | 2 | 1997 | 9 | 0.040 |
Why?
|
| Cell Survival | 3 | 2003 | 169 | 0.040 |
Why?
|
| Drug Hypersensitivity | 1 | 1979 | 17 | 0.040 |
Why?
|
| Titrimetry | 1 | 1999 | 4 | 0.040 |
Why?
|
| Dreams | 1 | 1999 | 3 | 0.040 |
Why?
|
| Synaptic Transmission | 2 | 1998 | 46 | 0.040 |
Why?
|
| Psychoses, Substance-Induced | 1 | 1998 | 3 | 0.040 |
Why?
|
| Chicago | 2 | 1993 | 865 | 0.040 |
Why?
|
| Color Perception | 1 | 1998 | 6 | 0.040 |
Why?
|
| Delirium | 1 | 1999 | 36 | 0.040 |
Why?
|
| Lod Score | 3 | 2003 | 22 | 0.040 |
Why?
|
| Hypoxia | 1 | 1999 | 60 | 0.040 |
Why?
|
| Antihypertensive Agents | 1 | 1999 | 85 | 0.040 |
Why?
|
| Benserazide | 1 | 1998 | 1 | 0.040 |
Why?
|
| Stereotypic Movement Disorder | 1 | 1998 | 4 | 0.040 |
Why?
|
| Ultraviolet Rays | 1 | 2018 | 9 | 0.040 |
Why?
|
| Half-Life | 1 | 1998 | 18 | 0.040 |
Why?
|
| Tomography, Optical Coherence | 1 | 2018 | 16 | 0.040 |
Why?
|
| Osmolar Concentration | 1 | 2018 | 30 | 0.040 |
Why?
|
| Antisocial Personality Disorder | 1 | 1998 | 9 | 0.040 |
Why?
|
| Electronic Mail | 1 | 2018 | 2 | 0.040 |
Why?
|
| Videoconferencing | 1 | 2018 | 3 | 0.040 |
Why?
|
| North America | 1 | 1998 | 38 | 0.040 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2018 | 14 | 0.040 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 1998 | 38 | 0.040 |
Why?
|
| Descemet Membrane | 1 | 2017 | 1 | 0.040 |
Why?
|
| Endothelium, Corneal | 1 | 2017 | 2 | 0.040 |
Why?
|
| Collagen | 1 | 2018 | 102 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 1998 | 76 | 0.040 |
Why?
|
| Global Health | 1 | 2018 | 55 | 0.040 |
Why?
|
| Translating | 1 | 2017 | 5 | 0.040 |
Why?
|
| Anniversaries and Special Events | 1 | 2017 | 4 | 0.040 |
Why?
|
| Nerve Degeneration | 2 | 1997 | 55 | 0.040 |
Why?
|
| Peripheral Nerves | 1 | 1997 | 20 | 0.040 |
Why?
|
| Nurse Clinicians | 1 | 1997 | 25 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 1998 | 86 | 0.040 |
Why?
|
| Nerve Tissue | 1 | 1997 | 2 | 0.040 |
Why?
|
| Stereotaxic Techniques | 2 | 1997 | 27 | 0.040 |
Why?
|
| Electroencephalography | 2 | 1989 | 140 | 0.040 |
Why?
|
| Tegmentum Mesencephali | 3 | 1991 | 7 | 0.040 |
Why?
|
| Cells, Cultured | 4 | 2009 | 676 | 0.040 |
Why?
|
| Olfactory Bulb | 1 | 2016 | 16 | 0.040 |
Why?
|
| Locus Coeruleus | 1 | 2016 | 23 | 0.040 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 1996 | 1 | 0.040 |
Why?
|
| Genes | 1 | 1996 | 8 | 0.040 |
Why?
|
| Drug Tolerance | 2 | 2006 | 12 | 0.040 |
Why?
|
| Quality of Health Care | 1 | 2018 | 138 | 0.040 |
Why?
|
| Sneddon Syndrome | 1 | 1996 | 1 | 0.040 |
Why?
|
| Verbal Behavior | 1 | 1996 | 19 | 0.040 |
Why?
|
| Patient Care Team | 1 | 1998 | 140 | 0.040 |
Why?
|
| Models, Neurological | 1 | 1996 | 30 | 0.040 |
Why?
|
| Drug Storage | 1 | 1996 | 2 | 0.040 |
Why?
|
| Models, Anatomic | 1 | 1996 | 52 | 0.040 |
Why?
|
| Amphetamine | 4 | 1983 | 13 | 0.040 |
Why?
|
| Urinary Incontinence | 1 | 1996 | 24 | 0.030 |
Why?
|
| Oxidopamine | 2 | 1993 | 24 | 0.030 |
Why?
|
| Multiple Myeloma | 1 | 1996 | 30 | 0.030 |
Why?
|
| Ascorbic Acid | 1 | 1996 | 32 | 0.030 |
Why?
|
| Temperature | 1 | 1996 | 76 | 0.030 |
Why?
|
| Erectile Dysfunction | 1 | 1996 | 46 | 0.030 |
Why?
|
| Oxazines | 2 | 1992 | 8 | 0.030 |
Why?
|
| Homovanillic Acid | 4 | 1990 | 9 | 0.030 |
Why?
|
| Mortality | 1 | 1996 | 86 | 0.030 |
Why?
|
| Dependovirus | 1 | 2015 | 37 | 0.030 |
Why?
|
| Pediatrics | 1 | 1995 | 33 | 0.030 |
Why?
|
| Software | 1 | 1995 | 72 | 0.030 |
Why?
|
| Brain Ischemia | 1 | 1996 | 71 | 0.030 |
Why?
|
| Methysergide | 4 | 1998 | 7 | 0.030 |
Why?
|
| Probability | 1 | 2014 | 94 | 0.030 |
Why?
|
| Agent Orange | 1 | 1994 | 1 | 0.030 |
Why?
|
| Defoliants, Chemical | 1 | 1994 | 1 | 0.030 |
Why?
|
| Herbicides | 1 | 1994 | 3 | 0.030 |
Why?
|
| Pesticides | 1 | 1994 | 3 | 0.030 |
Why?
|
| Vietnam | 1 | 1994 | 6 | 0.030 |
Why?
|
| Environmental Pollution | 1 | 1994 | 2 | 0.030 |
Why?
|
| Occupational Diseases | 1 | 1994 | 21 | 0.030 |
Why?
|
| Remote Consultation | 1 | 2014 | 11 | 0.030 |
Why?
|
| Nursing Care | 1 | 2014 | 23 | 0.030 |
Why?
|
| Patient Care | 1 | 2014 | 34 | 0.030 |
Why?
|
| Tablets | 2 | 2009 | 8 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2013 | 113 | 0.030 |
Why?
|
| Physical Exertion | 1 | 1993 | 9 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2013 | 64 | 0.030 |
Why?
|
| Sleep Stages | 1 | 2013 | 34 | 0.030 |
Why?
|
| Muscular Diseases | 2 | 2004 | 18 | 0.030 |
Why?
|
| Anisotropy | 1 | 2013 | 58 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 10 | 2 | 2003 | 6 | 0.030 |
Why?
|
| 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine | 1 | 1993 | 17 | 0.030 |
Why?
|
| Chromosome Mapping | 2 | 2003 | 52 | 0.030 |
Why?
|
| Discrimination Learning | 1 | 1992 | 3 | 0.030 |
Why?
|
| Linkage Disequilibrium | 2 | 2003 | 47 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 2 | 2003 | 161 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 8 | 2 | 2003 | 5 | 0.030 |
Why?
|
| Italy | 1 | 2012 | 16 | 0.030 |
Why?
|
| Heart Diseases | 2 | 1985 | 73 | 0.030 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2013 | 81 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2006 | 394 | 0.030 |
Why?
|
| Random Allocation | 2 | 1996 | 146 | 0.030 |
Why?
|
| Injections | 1 | 1992 | 56 | 0.030 |
Why?
|
| Benztropine | 3 | 1988 | 6 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 6 | 2 | 2002 | 7 | 0.030 |
Why?
|
| Kidney Diseases | 1 | 1993 | 115 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 17 | 2 | 2001 | 9 | 0.030 |
Why?
|
| Fetal Stem Cells | 1 | 2011 | 1 | 0.030 |
Why?
|
| Pallidotomy | 1 | 2011 | 1 | 0.030 |
Why?
|
| Acupuncture Therapy | 1 | 2011 | 2 | 0.030 |
Why?
|
| Microsatellite Repeats | 2 | 2001 | 19 | 0.030 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2011 | 25 | 0.030 |
Why?
|
| Sleep Disorders, Intrinsic | 1 | 2011 | 7 | 0.030 |
Why?
|
| Urinary Bladder Diseases | 1 | 2011 | 8 | 0.030 |
Why?
|
| Psychotropic Drugs | 1 | 2011 | 23 | 0.030 |
Why?
|
| Mood Disorders | 1 | 2011 | 31 | 0.030 |
Why?
|
| Sickness Impact Profile | 1 | 2011 | 19 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2011 | 30 | 0.030 |
Why?
|
| Chromogranins | 1 | 1991 | 4 | 0.030 |
Why?
|
| Nerve Fibers | 1 | 1991 | 14 | 0.030 |
Why?
|
| Drug Evaluation | 2 | 1989 | 52 | 0.030 |
Why?
|
| Data Collection | 1 | 1991 | 107 | 0.030 |
Why?
|
| Rats, Inbred Strains | 3 | 1988 | 33 | 0.030 |
Why?
|
| Neurosurgery | 2 | 1990 | 49 | 0.030 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 1991 | 22 | 0.020 |
Why?
|
| Antibodies | 1 | 1991 | 65 | 0.020 |
Why?
|
| Drug Design | 1 | 2011 | 30 | 0.020 |
Why?
|
| Staphylococcal Infections | 1 | 1993 | 176 | 0.020 |
Why?
|
| Norway | 1 | 2010 | 2 | 0.020 |
Why?
|
| Community Health Planning | 1 | 2010 | 21 | 0.020 |
Why?
|
| Hydroxyindoleacetic Acid | 1 | 1990 | 1 | 0.020 |
Why?
|
| Forms and Records Control | 1 | 1990 | 10 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 1991 | 391 | 0.020 |
Why?
|
| Lamins | 1 | 2009 | 2 | 0.020 |
Why?
|
| Canada | 1 | 1990 | 56 | 0.020 |
Why?
|
| Phenethylamines | 1 | 1989 | 5 | 0.020 |
Why?
|
| Bethanechol Compounds | 1 | 1989 | 6 | 0.020 |
Why?
|
| Hippocampus | 1 | 2012 | 274 | 0.020 |
Why?
|
| DNA | 1 | 2009 | 125 | 0.020 |
Why?
|
| Chlorpromazine | 3 | 1985 | 11 | 0.020 |
Why?
|
| Extrapyramidal Tracts | 2 | 1996 | 3 | 0.020 |
Why?
|
| Environmental Pollutants | 1 | 1989 | 3 | 0.020 |
Why?
|
| Sexual Behavior | 1 | 1989 | 66 | 0.020 |
Why?
|
| Autoantibodies | 1 | 1990 | 100 | 0.020 |
Why?
|
| Psychological Tests | 2 | 1987 | 52 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2011 | 462 | 0.020 |
Why?
|
| Cervical Vertebrae | 1 | 1993 | 349 | 0.020 |
Why?
|
| Heart Arrest | 2 | 2001 | 58 | 0.020 |
Why?
|
| Deferoxamine | 1 | 1988 | 2 | 0.020 |
Why?
|
| Body Burden | 1 | 1988 | 9 | 0.020 |
Why?
|
| Cerebral Ventricles | 1 | 1988 | 23 | 0.020 |
Why?
|
| Methiothepin | 2 | 1999 | 5 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2009 | 303 | 0.020 |
Why?
|
| Oxadiazoles | 2 | 1999 | 12 | 0.020 |
Why?
|
| Drama | 1 | 1988 | 1 | 0.020 |
Why?
|
| History, 16th Century | 1 | 1988 | 3 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2001 | 451 | 0.020 |
Why?
|
| SSPE Virus | 1 | 1988 | 1 | 0.020 |
Why?
|
| Tropanes | 1 | 1988 | 4 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 1988 | 129 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 1988 | 70 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2010 | 428 | 0.020 |
Why?
|
| Antidepressive Agents, Tricyclic | 2 | 1998 | 23 | 0.020 |
Why?
|
| Propranolol | 3 | 1984 | 12 | 0.020 |
Why?
|
| Aripiprazole | 1 | 2006 | 7 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2007 | 124 | 0.020 |
Why?
|
| Receptors, Muscarinic | 1 | 1986 | 7 | 0.020 |
Why?
|
| Mice | 2 | 2009 | 1607 | 0.020 |
Why?
|
| Bismuth | 1 | 1986 | 2 | 0.020 |
Why?
|
| Gasoline | 1 | 1986 | 2 | 0.020 |
Why?
|
| Hydrocarbons, Brominated | 1 | 1986 | 2 | 0.020 |
Why?
|
| Valsalva Maneuver | 1 | 1986 | 4 | 0.020 |
Why?
|
| Sweating | 1 | 1986 | 4 | 0.020 |
Why?
|
| Imipramine | 1 | 1986 | 13 | 0.020 |
Why?
|
| Affective Symptoms | 1 | 2006 | 11 | 0.020 |
Why?
|
| Motor Skills Disorders | 1 | 2006 | 18 | 0.020 |
Why?
|
| Extremities | 1 | 1986 | 31 | 0.020 |
Why?
|
| Body Temperature | 1 | 1986 | 58 | 0.020 |
Why?
|
| Awareness | 1 | 2006 | 37 | 0.020 |
Why?
|
| Hemodynamics | 1 | 1986 | 83 | 0.020 |
Why?
|
| Anesthetics | 1 | 1986 | 25 | 0.020 |
Why?
|
| Demography | 1 | 2005 | 77 | 0.020 |
Why?
|
| Reaction Time | 1 | 2006 | 123 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2005 | 87 | 0.020 |
Why?
|
| Cerebellar Neoplasms | 1 | 2005 | 7 | 0.020 |
Why?
|
| Brain Stem Neoplasms | 1 | 2005 | 3 | 0.020 |
Why?
|
| Nausea | 1 | 1985 | 27 | 0.020 |
Why?
|
| Remission Induction | 1 | 2005 | 96 | 0.020 |
Why?
|
| Photic Stimulation | 1 | 2004 | 44 | 0.020 |
Why?
|
| Gyrus Cinguli | 1 | 2004 | 22 | 0.020 |
Why?
|
| Heart | 1 | 1985 | 91 | 0.020 |
Why?
|
| Bupropion | 1 | 1984 | 7 | 0.020 |
Why?
|
| Romania | 1 | 2004 | 1 | 0.020 |
Why?
|
| Australia | 1 | 2004 | 44 | 0.020 |
Why?
|
| Apolipoprotein E3 | 1 | 2004 | 17 | 0.020 |
Why?
|
| Medical Records | 1 | 2004 | 29 | 0.020 |
Why?
|
| Baclofen | 1 | 1984 | 15 | 0.020 |
Why?
|
| Remission, Spontaneous | 1 | 2003 | 9 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2005 | 184 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2003 | 58 | 0.010 |
Why?
|
| Risk | 1 | 2004 | 217 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2003 | 36 | 0.010 |
Why?
|
| DNA Primers | 1 | 2003 | 51 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2003 | 50 | 0.010 |
Why?
|
| Genetic Linkage | 1 | 2003 | 65 | 0.010 |
Why?
|
| Haplorhini | 1 | 1983 | 12 | 0.010 |
Why?
|
| Lithium | 1 | 1983 | 23 | 0.010 |
Why?
|
| Parasympathetic Nervous System | 1 | 1982 | 2 | 0.010 |
Why?
|
| Interpersonal Relations | 1 | 2003 | 105 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2003 | 246 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 1986 | 402 | 0.010 |
Why?
|
| Facial Hemiatrophy | 1 | 2002 | 2 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2002 | 9 | 0.010 |
Why?
|
| Exons | 1 | 2002 | 34 | 0.010 |
Why?
|
| Gene Dosage | 1 | 2002 | 23 | 0.010 |
Why?
|
| Echolalia | 1 | 1982 | 1 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2002 | 35 | 0.010 |
Why?
|
| Multifactorial Inheritance | 1 | 2002 | 24 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2001 | 6 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2001 | 8 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2001 | 6 | 0.010 |
Why?
|
| Gait | 2 | 2000 | 404 | 0.010 |
Why?
|
| Long-Term Care | 1 | 1982 | 58 | 0.010 |
Why?
|
| Hand | 1 | 2002 | 45 | 0.010 |
Why?
|
| Drug Resistance | 1 | 2001 | 55 | 0.010 |
Why?
|
| Drug Implants | 1 | 2001 | 11 | 0.010 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 1981 | 36 | 0.010 |
Why?
|
| Ovariectomy | 1 | 2001 | 26 | 0.010 |
Why?
|
| Growth Substances | 2 | 1991 | 41 | 0.010 |
Why?
|
| Estradiol | 1 | 2001 | 58 | 0.010 |
Why?
|
| Cebus | 1 | 2000 | 1 | 0.010 |
Why?
|
| Nitro Compounds | 1 | 2000 | 9 | 0.010 |
Why?
|
| Trihexyphenidyl | 3 | 1988 | 5 | 0.010 |
Why?
|
| Larynx | 1 | 2000 | 16 | 0.010 |
Why?
|
| Ethical Review | 1 | 1999 | 2 | 0.010 |
Why?
|
| Ethics Committees, Research | 1 | 1999 | 4 | 0.010 |
Why?
|
| New Guinea | 1 | 1999 | 2 | 0.010 |
Why?
|
| Federal Government | 1 | 1999 | 6 | 0.010 |
Why?
|
| Injections, Intraventricular | 1 | 1999 | 13 | 0.010 |
Why?
|
| Synucleins | 1 | 1999 | 7 | 0.010 |
Why?
|
| Research Subjects | 1 | 1999 | 13 | 0.010 |
Why?
|
| Cell Death | 1 | 1999 | 61 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 1999 | 40 | 0.010 |
Why?
|
| Postoperative Period | 2 | 1992 | 288 | 0.010 |
Why?
|
| Family Health | 1 | 1999 | 37 | 0.010 |
Why?
|
| Glial Cell Line-Derived Neurotrophic Factor | 1 | 1999 | 30 | 0.010 |
Why?
|
| Penicillins | 1 | 1999 | 12 | 0.010 |
Why?
|
| Central Nervous System Agents | 1 | 1999 | 8 | 0.010 |
Why?
|
| London | 1 | 1998 | 3 | 0.010 |
Why?
|
| Substrate Specificity | 1 | 1998 | 26 | 0.010 |
Why?
|
| Cerebrospinal Fluid Proteins | 1 | 1997 | 3 | 0.010 |
Why?
|
| Prion Diseases | 1 | 1997 | 3 | 0.010 |
Why?
|
| Benzodiazepinones | 1 | 1977 | 2 | 0.010 |
Why?
|
| Dyspnea | 1 | 1978 | 37 | 0.010 |
Why?
|
| Olivopontocerebellar Atrophies | 1 | 1997 | 1 | 0.010 |
Why?
|
| Shy-Drager Syndrome | 1 | 1997 | 1 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1982 | 770 | 0.010 |
Why?
|
| Vasculitis | 1 | 1997 | 32 | 0.010 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 1997 | 6 | 0.010 |
Why?
|
| Solutions | 1 | 1997 | 19 | 0.010 |
Why?
|
| Lymphoma | 1 | 1997 | 44 | 0.010 |
Why?
|
| Chromaffin Cells | 1 | 1997 | 1 | 0.010 |
Why?
|
| Autopsy | 1 | 1998 | 335 | 0.010 |
Why?
|
| C-Reactive Protein | 1 | 1997 | 125 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 1997 | 33 | 0.010 |
Why?
|
| General Surgery | 1 | 1997 | 49 | 0.010 |
Why?
|
| Astrocytes | 1 | 1997 | 122 | 0.010 |
Why?
|
| Boston | 1 | 1996 | 27 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 1997 | 277 | 0.010 |
Why?
|
| Age Distribution | 1 | 1996 | 94 | 0.010 |
Why?
|
| Survival Analysis | 1 | 1996 | 298 | 0.010 |
Why?
|
| Dopamine Antagonists | 2 | 1990 | 14 | 0.010 |
Why?
|
| Receptors, Drug | 1 | 1974 | 1 | 0.010 |
Why?
|
| Hyperthyroidism | 1 | 1974 | 11 | 0.010 |
Why?
|
| Infusions, Parenteral | 1 | 1993 | 13 | 0.010 |
Why?
|
| Duodenum | 1 | 1993 | 12 | 0.010 |
Why?
|
| Antigen-Antibody Complex | 1 | 1993 | 13 | 0.010 |
Why?
|
| Hypothyroidism | 1 | 1974 | 31 | 0.010 |
Why?
|
| Equipment Contamination | 1 | 1993 | 24 | 0.010 |
Why?
|
| Glomerulonephritis | 1 | 1993 | 23 | 0.010 |
Why?
|
| Cell Division | 1 | 1993 | 113 | 0.010 |
Why?
|
| Heart Atria | 1 | 1993 | 71 | 0.010 |
Why?
|
| Cerebrospinal Fluid | 1 | 1991 | 18 | 0.010 |
Why?
|
| Chromogranin A | 1 | 1991 | 13 | 0.010 |
Why?
|
| Rotation | 1 | 1991 | 142 | 0.010 |
Why?
|
| Pheochromocytoma | 1 | 1990 | 6 | 0.010 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 1990 | 11 | 0.010 |
Why?
|
| Culture Media | 1 | 1990 | 38 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1990 | 145 | 0.010 |
Why?
|
| Bethanechol | 1 | 1989 | 5 | 0.010 |
Why?
|
| Agriculture | 1 | 1989 | 4 | 0.010 |
Why?
|
| Industry | 1 | 1989 | 9 | 0.010 |
Why?
|
| China | 1 | 1989 | 59 | 0.010 |
Why?
|
| Personality Inventory | 1 | 1988 | 72 | 0.000 |
Why?
|
| Tranquilizing Agents | 2 | 1978 | 3 | 0.000 |
Why?
|
| Residence Characteristics | 1 | 1989 | 216 | 0.000 |
Why?
|
| Tremorine | 1 | 1986 | 2 | 0.000 |
Why?
|
| Naloxone | 1 | 1986 | 12 | 0.000 |
Why?
|
| In Vitro Techniques | 1 | 1986 | 213 | 0.000 |
Why?
|
| Morphine | 1 | 1986 | 79 | 0.000 |
Why?
|
| Myocardial Contraction | 1 | 1985 | 75 | 0.000 |
Why?
|
| Speech Articulation Tests | 1 | 1984 | 3 | 0.000 |
Why?
|
| Speech Intelligibility | 1 | 1984 | 12 | 0.000 |
Why?
|
| Electrocardiography | 1 | 1985 | 209 | 0.000 |
Why?
|
| Epidemiologic Methods | 1 | 1983 | 21 | 0.000 |
Why?
|
| Physostigmine | 1 | 1982 | 1 | 0.000 |
Why?
|
| Ambulatory Care | 1 | 1983 | 75 | 0.000 |
Why?
|
| Muscle Contraction | 1 | 1982 | 83 | 0.000 |
Why?
|
| Monoamine Oxidase | 1 | 1980 | 2 | 0.000 |
Why?
|
| Electrodiagnosis | 1 | 1980 | 4 | 0.000 |
Why?
|
| Evoked Potentials | 1 | 1980 | 18 | 0.000 |
Why?
|
| Eye Movements | 1 | 1980 | 20 | 0.000 |
Why?
|
| Gliosis | 1 | 1980 | 8 | 0.000 |
Why?
|
| Blood Platelets | 1 | 1980 | 49 | 0.000 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 1980 | 49 | 0.000 |
Why?
|
| Hospitalization | 1 | 1983 | 317 | 0.000 |
Why?
|
| Acetonitriles | 1 | 1978 | 1 | 0.000 |
Why?
|
| Liver Function Tests | 1 | 1978 | 24 | 0.000 |
Why?
|
| Ergot Alkaloids | 1 | 1977 | 1 | 0.000 |
Why?
|
| Dextroamphetamine | 1 | 1977 | 6 | 0.000 |
Why?
|
| Synapses | 1 | 1977 | 50 | 0.000 |
Why?
|
| Phentolamine | 1 | 1973 | 2 | 0.000 |
Why?
|
| Injections, Subcutaneous | 1 | 1973 | 32 | 0.000 |
Why?
|